Biohaven Lands $400M Upfront in Global Licensing Deal for Epilepsy Drug Opakalim
BHVN sits 93% above its 52-week low of $7.48.
Summary
Biohaven has entered a strategic global licensing agreement with SK Biopharmaceuticals for its Kv7 ion channel platform and lead candidate opakalim, a Phase 2/3 epilepsy drug. The deal brings $400 million in near-term cash ($350 million at closing, $50 million in 2027), up to $795 million in total milestones, and tiered royalties on U.S. sales. SK Biopharmaceuticals also assumes $245 million in future obligations to Knopp Biosciences and other Kv7 programs. This non-dilutive capital significantly strengthens Biohaven's balance sheet and extends its runway, while retaining long-term upside through milestones and royalties. The partnership leverages SK Biopharmaceuticals' proven epilepsy commercial infrastructure, including the XCOPRI launch team, providing a faster path to market without Biohaven building its own sales force. Topline results from the RISE3 trial are expected in 2H 2026, which will be a key catalyst for the program's value.
At the time of this announcement, BHVN was trading at $14.42 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $7.48 to $18.57. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.